Evaluation of Evolocumab (AMG 145) Efficacy in Diabetic Adults With Hypercholesterolemia/Mixed Dyslipidemia
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 424 participants.
Also called NCT02739984
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; triple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 424 participants
- Sponsor
- Registry
-
NCT02739984 -
2015-004711-21
-
- Other papers using this trial's data
- Efficacy and safety of evolocumab in individuals with type 2 diabetes mellitus: primary results of the randomised controlled BANTING study
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Belgium, Canada, Italy, Mexico, Poland, Spain
- Registry status
- Completed
Technical summary
Registry record NCT02739984. Randomized; triple masking; primary purpose treatment. Start 2016-05-17 (actual); primary completion 2017-08-03 (actual). Results posted on 2018-08-31.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Evaluation of Evolocumab (AMG 145) Efficacy in Diabetic Adults With Hypercholesterolemia/Mixed Dyslipidemia
- Acronym
- BANTING
- Condition
- Hypercholesterolemia
- Condition
- Mixed Dyslipidemia
- Condition
- Type 2 Diabetes
- Intervention (Biological)
- Evolocumab
- Intervention (Drug)
- Placebo to Evolocumab
- Lead sponsor
- Amgen
Record details
- Record id
cardio:ct-nct02739984- Content hash
c691cc4fe6116d29bd01d0f7afc7ecf75285693af243764824c6960a18823919